Investigational Drug Information for Irsogladine
✉ Email this page to a colleague
What is the development status for investigational drug Irsogladine?
Irsogladine is an investigational drug.
There have been 4 clinical trials for Irsogladine.
The most recent clinical trial was a Phase 1 trial, which was initiated on February 1st 2022.
The most common disease conditions in clinical trials are Gastritis, Stomach Ulcer, and Peptic Ulcer. The leading clinical trial sponsors are Boryung Pharmaceutical Co., Ltd, The Catholic University of Korea, and Kukje Pharma.
There are zero US patents protecting this investigational drug and zero international patents.
Summary for Irsogladine
| US Patents | 1,207 |
| International Patents | 9,774 |
| US Patent Applications | 4,254 |
| WIPO Patent Applications | 1,616 |
| Japanese Patent Applications | 561 |
| Clinical Trial Progress | Phase 1 (2022-02-01) |
| Vendors | 55 |
Recent Clinical Trials for Irsogladine
| Title | Sponsor | Phase |
|---|---|---|
| Therapeutic Effect of Isoladine Maleate on Small Intestinal Mucosal Injury Associated With NSAIDS in Population | Lee's Pharmaceutical Limited | Phase 4 |
| [KJ-INT-002] BE Study | Kukje Pharma | Phase 1 |
| A Study to Compare the Pharmacokinetics of Lafutidine and Irsogladine Maleate Tablet | Boryung Pharmaceutical Co., Ltd | Phase 1 |
Clinical Trial Summary for Irsogladine
Top disease conditions for Irsogladine
Top clinical trial sponsors for Irsogladine
US Patents for Irsogladine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Irsogladine | ⤷ Sign Up | Method of diagnosing and treating cancer using B-catenin splice variants | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | ⤷ Sign Up |
| Irsogladine | ⤷ Sign Up | Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers | Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) | ⤷ Sign Up |
| Irsogladine | ⤷ Sign Up | Use of inhibitors of Bruton'S tyrosine kinase (Btk) | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Irsogladine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Irsogladine | Australia | AU2006213610 | 2025-02-10 | ⤷ Sign Up |
| Irsogladine | Canada | CA2596845 | 2025-02-10 | ⤷ Sign Up |
| Irsogladine | Denmark | DK1851340 | 2025-02-10 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
